Bivigam is an immune globulin intravenous human (IVIG) product provided by ADMA Biologics. It is indicated for the treatment of patients with primary humoral immunodeficiency (PI), including common variable immunodeficiency (CVID), X linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID). Bivigam offers proven protection and simplifies access to high-quality IVIG treatment for patients, with potential financial assistance available.
Bivigam is contraindicated in patients who have had severe systemic reactions to human immune globulin and in patients with IgA deficiency and antibodies to IgA. Thrombosis and renal dysfunction are potential risks associated with IVIG treatment, but Bivigam, which does not contain sucrose, minimizes these risks. Severe hypersensitivity reactions may occur, and acute renal dysfunction, osmotic nephrosis, and death have been reported with the use of IVIG products. Regular monitoring of renal function is important, and appropriate treatment should be administered in case of hypersensitivity reactions.
Generated from the website